Axplora

Axplora is a leading CDMO and active pharmaceutical ingredient (API) manufacturer formed by combining the expertise and capabilities of Farmabios, Novasep, and PharmaZell. The company supports the entire lifecycle of pharmaceuticals with ~50 CDMO projects in clinical development and 100+ commercial APIs manufactured annually.

Core Capabilities

Axplora specializes in custom development and upscaling of complex API production processes, with particular strength in:

• ADC Manufacturing: €8 million investment in Le Mans facility for antibody-drug conjugate production
• HPAPI Manufacturing: Highly potent active pharmaceutical ingredients across multiple therapeutic areas
• Hazardous Chemistry: Advanced capabilities in cryogenic chemistry, electrochemistry, and enzymatic reactions
• Chromatography: Industrial-scale purification technologies
• Steroids: Including sterile steroid APIs for various treatment areas
• Process Development & Scale-up: From clinical phases through commercial manufacturing

Therapeutic Focus

The company serves anti-cancer, women's health, respiratory, metabolic (including GLP-1 receptor agonists), and inflammatory disease markets. Axplora maintains a targeted portfolio of small molecule APIs for the generic industry.

Global Infrastructure

With 2,400 employees across ten API manufacturing sites in Europe and India, plus an R&D center in Wilmington (US), Axplora provides competitive global supply capabilities. The company serves over 900 customers and has completed 50+ customer audits over the last three years.